Cardiovascular Outcomes After Tixagevimab and Cilgavimab use for Pre-exposure Prophylaxis Against COVID-19: A Population-based Propensity-matched Cohort Study

被引：11
作者：
Birabaharan, Morgan [1 ,7 ]
Hill, Eddie [1 ]
Begur, Maedha [1 ]
Kaelber, David C. [2 ,3 ,4 ,5 ]
Martin, Thomas C. S. [1 ]
Mehta, Sanjay R. [1 ,6 ]
机构：
[1] Univ Calif San Diego, Dept Med, Div Infect Dis & Global Publ Hlth, La Jolla, CA USA
[2] Metrohlth Syst, Ctr Clin Informat Res & Educ, Cleveland, OH USA
[3] Case Western Reserve Univ, Sch Med, Dept Internal Med, Cleveland, OH USA
[4] Case Western Reserve Univ, Sch Med, Dept Pediat, Cleveland, OH USA
[5] Case Western Reserve Univ, Sch Med, Dept Populat & Quantitat Hlth Sci, Cleveland, OH USA
[6] San Diego Vet Affairs Healthcare Syst, San Diego, CA USA
[7] Univ Calif San Diego, Div Infect Dis & Global Publ Hlth, 9500 Gilman Dr, San Diego, CA 92093 USA
来源：
CLINICAL INFECTIOUS DISEASES | 2023年 / 76卷 / 08期
关键词：
tixagevimab; cilgavimab; evusheld; cardiovascular; COVID; 19;
D O I：
10.1093/cid/ciac894
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Tixagevimab and cilgavimab treatment was associated with higher rates of cardiovascular events in a post hoc analysis of a phase 3 trial. In this large population-based propensity-matched study, we found no increased risk of cardiovascular events up to 90 days after tixagevimab and cilgavimab administration, including in patients with pre-existing cardiovascular disease.
引用
收藏
页码：1500 / 1503
页数：4
相关论文
共 9 条
[1]  
Astronautix, US
[2]   COVID-19 and Cardiovascular Disease [J].
Clerkin, Kevin J. ;
Fried, Justin A. ;
Raikhelkar, Jayant ;
Sayer, Gabriel ;
Griffin, Jan M. ;
Masoumi, Amirali ;
Jain, Sneha S. ;
Burkhoff, Daniel ;
Kumaraiah, Deepa ;
Rabbani, LeRoy ;
Schwartz, Allan ;
Uriel, Nir .
CIRCULATION, 2020, 141 (20) :1648-1655
[3]  
FDA, US
[4]   Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study [J].
Katsoularis, Ioannis ;
Fonseca-Rodriguez, Osvaldo ;
Farrington, Paddy ;
Lindmark, Krister ;
Connolly, Anne-Marie Fors .
LANCET, 2021, 398 (10300) :599-607
[5]   Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19 [J].
Levin, Myron J. ;
Ustianowski, Andrew ;
De Wit, Stephane ;
Launay, Odile ;
Avila, Miles ;
Templeton, Alison ;
Yuan, Yuan ;
Seegobin, Seth ;
Ellery, Adam ;
Levinson, Dennis J. ;
Ambery, Philip ;
Arends, Rosalinda H. ;
Beavon, Rohini ;
Dey, Kanika ;
Garbes, Pedro ;
Kelly, Elizabeth J. ;
Koh, Gavin C. K. W. ;
Near, Karen A. ;
Padilla, Kelly W. ;
Psachoulia, Konstantina ;
Sharbaugh, Audrey ;
Streicher, Katie ;
Pangalos, Menelas N. ;
Esser, Mark T. .
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (23) :2188-2200
[6]   Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial [J].
Montgomery, Hugh ;
Hobbs, F. D. Richard ;
Padilla, Francisco ;
Arbetter, Douglas ;
Templeton, Alison ;
Seegobin, Seth ;
Kim, Kenneth ;
Campos, Jesus Abraham Simon ;
Arends, Rosalinda H. ;
Brodek, Bryan H. ;
Brooks, Dennis ;
Garbes, Pedro ;
Jimenez, Julieta ;
Koh, Gavin C. K. W. ;
Padilla, Kelly W. ;
Streicher, Katie ;
Viani, Rolando M. ;
Alagappan, Vijay ;
Pangalos, Menelas N. ;
Esser, Mark T. .
LANCET RESPIRATORY MEDICINE, 2022, 10 (10) :985-996
[7]  
Singson JRC, 2022, MMWR-MORBID MORTAL W, V71, P878, DOI 10.15585/mmwr.mm7127a3
[8]  
Wiemken TL., 2023, Clinical Infectious Diseases
[9]   Long-term cardiovascular outcomes of COVID-19 [J].
Xie, Yan ;
Xu, Evan ;
Bowe, Benjamin ;
Al-Aly, Ziyad .
NATURE MEDICINE, 2022, 28 (03) :583-+
1